TRHC - Tabula estimates higher-than-expected Q4 revenues

• Tabula Rasa HealthCare ( NASDAQ: TRHC ) has issued its preliminary results for Q4, with expected revenue in the range of $82M-$83M, higher than its prior guidance range of $77.5M-$80.5M.
• The unaudited estimated revenue range from continuing operations also exceeds the current consensus estimate of $78.49M. Tabula is set to release its full earnings report in early March.
• Interim CEO Brian Adams said: "We finished 2022 on a strong note, with our preliminary unaudited fourth quarter estimated revenue exceeding the high-end of the guidance range we provided on November 3, 2022. Entering 2023, we are encouraged by the underlying growth of our core PACE market and the exciting opportunities in adjacent markets to provide solutions to help manage the most complex patients in our healthcare system."
• Tabula ( TRHC ) is currently trading around +3.87% premarket.

For further details see: